Eli Lilly’s Obesity Pill Orforglipron Challenges Novo Nordisk’s Oral Wegovy in Weight-Loss Market Race August 24, 2025 The obesity drug market, projected to surpass $73 billion by 2034, is witnessing a fierce competition between pharmaceutical giants Eli Lilly and Novo Nordisk. Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, is emerging as a significant rival to … Read more
Crunch Time for Trade Talks as Trump Deadline Nears Washington, D.C. – July 27, 2025 – As the August 1 deadline for President Donald Trump’s trade negotiations looms, global markets and foreign governments are bracing for the reimposition of steep tariffs on dozens of countries. Initially announced on April 2, 2025, as part of Trump’s … Read more
Eli Lilly’s Orforglipron Clears First Late-Stage Trial, Boosts Weight Loss Hopes April 17, 2025 Indianapolis, IN – Eli Lilly’s experimental oral weight reduction tablet, orforglipron, met its objectives within the first of seven late-stage trials, serving to Sort 2 diabetes sufferers lose 7.9% of physique weight (16 kilos) and decrease blood sugar over 40 weeks, … Read more
Trump Indicators Pharmaceutical Tariffs Are Coming, But Shares Rise in Defiance April 9, 2025 – Washington, D.C. – President Donald Trump doubled down on his commerce warfare rhetoric Tuesday night time, declaring at a Nationwide Republican Congressional Committee dinner that “main” tariffs on pharmaceutical imports are imminent, a transfer he insists will “carry drug manufacturing … Read more
Eli Lilly to Unveil Trial Data for Oral Weight Loss Drug Orforglipron [City, Date] – Pharmaceutical giant Eli Lilly is set to release highly anticipated clinical trial data for its experimental oral weight loss drug, orforglipron, as the race to dominate the booming obesity treatment market intensifies. The upcoming data could position the company as … Read more